Her team recently developed a small nanocarrier that actively delivers a poly (ADP-ribose) polymerase (PARP) inhibitor and a ...

In January 2024, the FDA approved erdafitinib (Balversa) for adult patients with locally advanced or metastatic urothelial ...

In this cohort study, in situ breast cancer decreased since 2009, consistent with decreasing use of screening mammography since the ...

About The Study: In this cohort study, in situ breast cancer decreased since 2009, consistent with decreasing use of screening mammography since the 2009 U.S. Preventive Services Task Force guideline ...

Australia has one of the highest skin cancer rates globally, with nearly 19,000 Australians diagnosed with invasive melanoma ...

Some early breast cancer patients can safely avoid specific surgeries, according to two studies exploring ways to lessen ...

If you have a diagnosis, your doctor may need to find out if cancer cells have spread, though they won’t do this for melanoma in situ. The first step is to perform a sentinel node biopsy.

Nogapendekin alfa is under clinical development by ImmunityBio and currently in Phase II for Metastatic Colorectal Cancer.

Nogapendekin alfa is under clinical development by ImmunityBio and currently in Phase II for Ovarian Cancer. According to GlobalData, Phase II drugs for Ovarian Cancer have a 26% phase transition ...

In Kashmir, lifestyle changes are helping cervical cancer cases rise, years after cultural factors limited incidence ...

Engineered probiotics, mainly bacterial probiotics, are an emerging platform for in situ delivery of therapeutics, including anticancer therapies, to the gut. Writing in Cell Chemical Biology, ...